Nachrichten zur Transgene S.A. Aktie

BioInvent and Transgene presented promising phase I/IIa data on BT-001 at ESMO in Barcelona this weekend. BioStock contacted BioInvent’s CMO,…

BioInvent has released additional positive preliminary efficacy data from its ongoing phase IIa dose expansion study of BI-1808 as a…

Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops…

TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted…

Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based…

2023 Full-year results and business update …

Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a…

Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based…

…

BioInvent and its partner Transgene have reported positive results in the phase I/IIa study with the oncolytic virus BT-001. In…

LUND, SE / ACCESSWIRE / May 25, 2023 / BioInvent International (STO:BINV)Treatment of all Phase 1a cohorts in monotherapy completed…

Indee Labs research collaboration with GenScript aims to develop a DNA knock-in kit for Hydropore™ to enable large transgene inserts…